Zelira Therapeutics brings deep
pharmaceutical expertise to the
development and commercialisation of our
proprietary cannabinoid-based medicines.
Zelira Therapeutics…with our focus on specific
conditions, we are ‘reimagining healthcare’
for millions of people underserved by
We are committed to building patient and
doctor confidence in our medicines with
an ethical, evidence-based approach,
applying world-class science and
conducting clinical trials.
Zelira Therapeutics - Global Leader in cannabinoid-based medicine
Zelira Therapeutics Ltd is a leading global cannabinoid-based biopharmaceutical company with access to the world’s largest and fastest growing markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets. The Company is focused on developing branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its Rx business, including insomnia, autism and chronic non-cancer pain.
Recent Video and Audio from Zelira Therapeutics
Zelira Chairman Presentation at Cantor Fitzgerald International Cannabis Forum
Hear the latest business updates from Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Dr Oludare Odumosu.
Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Dr Oludare Odumosu deliver a slide presentation and answer investor questions as part of a business update.
Zelira product helping young patient with autism spectrum disorder
CEO Oludare Odumosu and Chairman Osagie Imasogie presentation at the Zelira AGM 2022
Zelira to launch a suite of new cannabinoid-based products in FY22 – Proactive
Zelira Therapeutics and Curtin University partner on research of proprietary technology that demonstrates significant uptake of CBD into the brain